|1.||Haranishi, Yasunori: 2 articles (03/2015 - 02/2010)|
|2.||Terada, Tadanori: 2 articles (03/2015 - 02/2010)|
|3.||Sata, Takeyoshi: 2 articles (03/2015 - 02/2010)|
|4.||Hara, Koji: 2 articles (03/2015 - 02/2010)|
|5.||Dohi, Toshihiro: 2 articles (10/2014 - 08/2008)|
|6.||Motoyama, Naoyo: 2 articles (10/2014 - 08/2008)|
|7.||Kitayama, Tomoya: 2 articles (10/2014 - 08/2008)|
|8.||Morita, Katsuya: 2 articles (10/2014 - 08/2008)|
|9.||Hermanns, Henning: 2 articles (07/2014 - 11/2008)|
|10.||Werdehausen, Robert: 2 articles (07/2014 - 11/2008)|
11/01/2013 - "In order to clarify the possibility of targeting GlyT2 for the treatment of pain, we have used an integrated approach comprising in vitro pharmacology, selectivity, bioavailability, in vivo efficacy and safety assessment to analyse the properties and efficacy of ALX-1393 and Org-25543, the two published GlyT2 inhibitors from which in vivo data are available. "
02/01/2010 - "This study demonstrates the antinociceptive action of ALX1393 on acute pain. "
02/01/2010 - "In this study, we examined whether a selective GlyT2 inhibitor, ALX1393, elicits an antinociceptive effect in a rat acute pain model. "
02/01/2010 - "In the formalin test, ALX1393 inhibited pain behaviors in a dose-dependent manner, both in the early and late phases, although the influence was greater in the late phase. "
02/01/2010 - "The antinociceptive effect of intrathecal administration of glycine transporter-2 inhibitor ALX1393 in a rat acute pain model."
|3.||Neuralgia (Stump Neuralgia)
03/01/2015 - "The present study examined the antinociceptive effect of intracerebroventricular (i.c.v.) administration of the selective GlyT2 inhibitor ALX1393 on inflammatory and neuropathic pain in experimental models. "
07/01/2014 - "In the chronic constriction injury model of neuropathic pain, male Wistar rats received specific GlyT1 and GlyT2 inhibitors (ALX5407 and ALX1393; Sigma-Aldrich, St. Louis, MO) or vehicle for 14 days via subcutaneous osmotic infusion pumps (n = 6). "
03/01/2015 - "Antinociceptive effect of intracerebroventricular administration of glycine transporter-2 inhibitor ALX1393 in rat models of inflammatory and neuropathic pain."
11/21/2008 - "In the present study, we investigated the effects of the spinally applied glycine transporter inhibitors ALX 5407 (GlyT1) and ALX 1393 (GlyT2) on nociceptive behavior in the chronic constriction injury model of neuropathic pain in male Wistar rats. "
08/01/2008 - "In this study, we demonstrated that i.v. or intrathecal administration of GlyT1 inhibitors, cis-N-methyl-N-(6-methoxy-1-phenyl-1,2,3,4-tetrahydronaphthalen-2-yl methyl)amino methylcarboxylic acid (ORG25935) or sarcosine, and GlyT2 inhibitors, 4-benzyloxy-3,5-dimethoxy-N-[1-(dimethylaminocyclopently)-methyl]benzamide (ORG25543) and (O-[(2-benzyloxyphenyl-3-fluorophenyl)methyl]-L-serine) (ALX1393), or knockdown of spinal GlyTs by small interfering RNA of GlyTs mRNA produced a profound antiallodynia effect in a partial peripheral nerve ligation model and other neuropathic pain models in mice. "
03/01/2015 - "In the CCI rats, ALX1393 inhibited mechanical and cold hyperalgesia in a dose-dependent manner. "
07/01/2014 - "Both ALX5407 and ALX1393 ameliorated thermal hyperalgesia and mechanical allodynia in a time- and dose-dependent manner. "
01/01/2010 - "The GlyT2 inhibitor ALX1393, but not the GlyT1 inhibitor sarcosine, suppressed dynamic and static allodynia at the herpetic and postherpetic stages. "
01/01/2010 - "Intrathecal ALX1393 suppressed dynamic allodynia induced by intrathecal strychnine and N-methyl-D-aspartate (NMDA). "
10/01/2014 - "Effects of GlyT2 inhibitors, ORG 25543 and ALX 1393, and GlyT1 inhibitors, ORG 25935, and knockdown of the expression of spinal GlyTs protein by GlyTs siRNA on pain-like behaviors, such as allodynia, withdrawal threshold, guarding behavior, and limb-use abnormality, were examined in the femur bone cancer model mice. "
|5.||Respiratory Insufficiency (Respiratory Failure)
|1.||N- methyl- N- (6- methoxy- 1- phenyl- 1,2,3,4- tetrahydronaphthalen- 2- ylmethyl)aminomethylcarboxylic acid
|3.||Small Interfering RNA (siRNA)
|4.||Glycine Plasma Membrane Transport Proteins
|6.||Messenger RNA (mRNA)
|7.||4- benzyloxy- 3,5- dimethoxy- N- (1- (dimethylaminocyclopently)methyl)benzamide
|8.||(R)- (N- (3- (4'- fluorophenyl)- 3- (4'- phenylphenoxy)propyl))sarcosine
|10.||Glycine (Aminoacetic Acid)
|1.||Transplantation (Transplant Recipients)
|4.||Infusion Pumps (Infusion Pump)